Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

471
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
471
Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

671
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
671
Antiasthma Drugs: β2-Adrenoceptor Agonists01:25

Antiasthma Drugs: β2-Adrenoceptor Agonists

623
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
623
Drugs Used in Lower Respiratory Disorders: Overview01:17

Drugs Used in Lower Respiratory Disorders: Overview

708
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
708
COPD: Pathogenesis and Clinical Features01:20

COPD: Pathogenesis and Clinical Features

688
Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
688
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids01:25

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids

446
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
446

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A study to assess the levels of free protein S in pregnant and nonpregnant women in a tertiary care center in Western Maharashtra.

Asian journal of transfusion science·2026
Same author

BDAA, a yellow fever virus NS4B inhibitor, is effective during therapeutic treatment in a hamster model of yellow fever.

Antiviral research·2026
Same author

In Vitro Regeneration Strategies in Woody Citrus of Northeast India (<i>Citrus jambhiri</i> and <i>Citrus aurantifolia</i>).

Plants (Basel, Switzerland)·2026
Same author

Utility of pre-operative magnetic resonance imaging (pelvis and abdomen) and combined tumour markers HE4 and CA125 in diagnosing early and advanced carcinoma endometrium.

Medical journal, Armed Forces India·2026
Same author

Correction to: Neurosurgical management of paediatric central nervous system tumours in low, middle and high-income countries: a multi-centre, international, cross-sectional study.

Neurosurgical review·2026
Same author

From nicotine to SARS-CoV-2 antivirals with potent in vivo efficacy and a broad anti-coronavirus spectrum.

Nature communications·2026

Related Experiment Video

Updated: Oct 13, 2025

Sublingual Immunotherapy as an Alternative to Induce Protection Against Acute Respiratory Infections
16:56

Sublingual Immunotherapy as an Alternative to Induce Protection Against Acute Respiratory Infections

Published on: August 30, 2014

17.2K

ProLung™-budesonide Inhibits SARS-CoV-2 Replication and Reduces Lung Inflammation.

Kameswari S Konduri1, Ram Pattisapu1, Jogi Pattisapu2

  • 1VGSK Technologies, Inc, Madison, WI USA.

Archives of Pharmacology and Therapeutics
|November 12, 2021
PubMed
Summary

ProLung™-budesonide effectively inhibited SARS-CoV-2 replication and reduced lung inflammation and airway hyperresponsiveness in preclinical models. This novel inhaled budesonide formulation shows promise as a potential COVID-19 treatment.

More Related Videos

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
07:28

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

Published on: April 6, 2017

40.9K
Protective Efficacy and Pulmonary Immune Response Following Subcutaneous and Intranasal BCG Administration in Mice
06:32

Protective Efficacy and Pulmonary Immune Response Following Subcutaneous and Intranasal BCG Administration in Mice

Published on: September 19, 2016

10.8K

Related Experiment Videos

Last Updated: Oct 13, 2025

Sublingual Immunotherapy as an Alternative to Induce Protection Against Acute Respiratory Infections
16:56

Sublingual Immunotherapy as an Alternative to Induce Protection Against Acute Respiratory Infections

Published on: August 30, 2014

17.2K
Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
07:28

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

Published on: April 6, 2017

40.9K
Protective Efficacy and Pulmonary Immune Response Following Subcutaneous and Intranasal BCG Administration in Mice
06:32

Protective Efficacy and Pulmonary Immune Response Following Subcutaneous and Intranasal BCG Administration in Mice

Published on: September 19, 2016

10.8K

Area of Science:

  • Pulmonology
  • Virology
  • Pharmacology

Background:

  • Inhaled budesonide is beneficial for COVID-19 patients.
  • ProLung™-budesonide offers sustained, low-dose budesonide delivery.
  • Its effect on SARS-CoV-2 replication and lung inflammation requires investigation.

Purpose of the Study:

  • Evaluate ProLung™-budesonide efficacy against SARS-CoV-2 in vitro.
  • Assess its anti-inflammatory effects in a lung inflammation animal model.
  • Determine its impact on airway hyperresponsiveness.

Main Methods:

  • SARS-CoV-2 infected cells treated with ProLung™-budesonide; virus yield measured.
  • Ovalbumin-sensitized mice received aerosolized ProLung™-budesonide, budesonide, or carrier.
  • Evaluated histopathology, EM, airway hyperresponsiveness (AHR), and eosinophil peroxidase (EPO) in bronchoalveolar lavage (BAL).

Main Results:

  • ProLung™-budesonide significantly inhibited SARS-CoV-2 replication (Selectivity Index >24).
  • Weekly ProLung™-budesonide and daily budesonide reduced lung inflammation and EPO.
  • ProLung™-budesonide localized in type II pneumocytes, decreased AHR and EPO.

Conclusions:

  • ProLung™-budesonide demonstrated significant SARS-CoV-2 inhibition in vitro.
  • It reduced lung inflammation, AHR, and EPO in an animal model.
  • This formulation may be a potential inhaled treatment for COVID-19.